SOHM, Inc., Unveils Genetically Engineered Ovarian Cancer Cell Line Using ABBIE(TM) Platform to Accelerate GYS1 Drug Discovery
SOHM, Inc. (OTC:SHMN) has successfully developed a genetically modified ovarian cancer cell line (SKOV3) that overexpresses the GYS1 gene using their proprietary ABBIE™ platform. This breakthrough provides a valuable tool for screening GYS1 inhibitors, as GYS1 is a crucial enzyme in cellular energy metabolism linked to cancer cell survival. The engineered cell line, SKOV3-GYS1+, offers a ready-to-use system for evaluating GYS1-targeted compounds, particularly relevant for aggressive cancers like ovarian, breast, and pancreatic malignancies.
The ABBIE™ platform enables high-specificity gene editing without viral vectors, and SOHM plans to expand its engineered cell line portfolio for metabolic and immuno-oncology targets throughout 2025.
SOHM, Inc. (OTC:SHMN) ha sviluppato con successo una linea cellulare di cancro ovarico geneticamente modificata (SKOV3) che sovraesprime il gene GYS1 utilizzando la loro piattaforma proprietaria ABBIE™. Questa innovazione rappresenta uno strumento prezioso per il screening di inibitori di GYS1, poiché GYS1 è un enzima fondamentale nel metabolismo energetico cellulare, collegato alla sopravvivenza delle cellule tumorali. La linea cellulare ingegnerizzata, SKOV3-GYS1+, offre un sistema pronto all'uso per valutare composti mirati a GYS1, particolarmente rilevante per tumori aggressivi come quelli ovarici, mammari e pancreatici.
La piattaforma ABBIE™ consente un editing genico ad alta specificità senza l'uso di vettori virali, e SOHM prevede di ampliare il proprio portafoglio di linee cellulari ingegnerizzate per bersagli metabolici e di immuno-oncologia nel corso del 2025.
SOHM, Inc. (OTC:SHMN) ha desarrollado con éxito una línea celular de cáncer de ovario modificada genéticamente (SKOV3) que sobreexpresa el gen GYS1 utilizando su plataforma patentada ABBIE™. Este avance proporciona una herramienta valiosa para la detección de inhibidores de GYS1, ya que GYS1 es una enzima crucial en el metabolismo energético celular relacionada con la supervivencia de las células cancerosas. La línea celular modificada, SKOV3-GYS1+, ofrece un sistema listo para usar para evaluar compuestos dirigidos a GYS1, especialmente relevante para cánceres agresivos como los de ovario, mama y páncreas.
La plataforma ABBIE™ permite una edición genética de alta especificidad sin vectores virales, y SOHM planea ampliar su cartera de líneas celulares modificadas para objetivos metabólicos e inmunooncológicos durante 2025.
SOHM, Inc. (OTC:SHMN)는 독자적인 ABBIE™ 플랫폼을 사용하여 GYS1 유전자를 과발현하는 유전자 변형 난소암 세포주(SKOV3)를 성공적으로 개발했습니다. 이 획기적인 성과는 GYS1이 암세포 생존과 관련된 세포 에너지 대사에서 중요한 효소임을 감안할 때, GYS1 억제제 스크리닝에 매우 유용한 도구를 제공합니다. 개발된 세포주 SKOV3-GYS1+는 난소암, 유방암, 췌장암과 같은 공격적인 암에 특히 적합한 GYS1 표적 화합물 평가에 즉시 사용할 수 있는 시스템을 제공합니다.
ABBIE™ 플랫폼은 바이러스 벡터 없이 높은 특이성의 유전자 편집을 가능하게 하며, SOHM은 2025년까지 대사 및 면역항암 표적을 위한 유전자 변형 세포주 포트폴리오를 확장할 계획입니다.
SOHM, Inc. (OTC:SHMN) a développé avec succès une lignée cellulaire de cancer de l'ovaire génétiquement modifiée (SKOV3) surexprimant le gène GYS1 grâce à leur plateforme propriétaire ABBIE™. Cette avancée constitue un outil précieux pour le criblage des inhibiteurs de GYS1, car GYS1 est une enzyme clé du métabolisme énergétique cellulaire liée à la survie des cellules cancéreuses. La lignée cellulaire modifiée, SKOV3-GYS1+, offre un système prêt à l'emploi pour évaluer des composés ciblant GYS1, particulièrement pertinent pour les cancers agressifs tels que ceux de l'ovaire, du sein et du pancréas.
La plateforme ABBIE™ permet une édition génétique à haute spécificité sans vecteurs viraux, et SOHM prévoit d'élargir son portefeuille de lignées cellulaires modifiées pour des cibles métaboliques et en immuno-oncologie tout au long de 2025.
SOHM, Inc. (OTC:SHMN) hat erfolgreich eine genetisch veränderte Eierstockkrebs-Zelllinie (SKOV3) entwickelt, die das GYS1-Gen mithilfe ihrer proprietären ABBIE™-Plattform überexprimiert. Dieser Durchbruch bietet ein wertvolles Werkzeug zum Screening von GYS1-Inhibitoren, da GYS1 ein entscheidendes Enzym im zellulären Energiestoffwechsel ist, das mit dem Überleben von Krebszellen verbunden ist. Die entwickelte Zelllinie SKOV3-GYS1+ stellt ein gebrauchsfertiges System zur Bewertung von GYS1-gerichteten Verbindungen dar, was besonders für aggressive Krebsarten wie Eierstock-, Brust- und Bauchspeicheldrüsenkrebs relevant ist.
Die ABBIE™-Plattform ermöglicht eine hochspezifische Genbearbeitung ohne virale Vektoren, und SOHM plant, sein Portfolio an genetisch veränderten Zelllinien für metabolische und immunonkologische Zielstrukturen im Laufe des Jahres 2025 zu erweitern.
- Development of novel SKOV3-GYS1+ cell line enables rapid screening of GYS1 inhibitors
- ABBIE™ platform demonstrates capability for high-efficiency gene editing with low off-target effects
- Company plans portfolio expansion into metabolic and immuno-oncology targets in 2025
- None.
CHINO HILLS, CALIFORNIA / ACCESS Newswire / May 6, 2025 / SOHM, Inc. (OTC PINK:SHMN), a biotech company at the forefront of precision cellular engineering, announced today the successful development of a genetically modified ovarian cancer cell line (SKOV3) overexpressing the GYS1 gene, using its proprietary gene editing platform, ABBIE™. This breakthrough establishes a powerful tool for the rapid screening of novel glycogen synthase 1 (GYS1) inhibitors and underscores SOHM's capacity to swiftly generate custom-engineered cell models to support targeted drug development.
GYS1 (glycogen synthase 1) is a pivotal enzyme in cellular energy metabolism, with emerging evidence linking its overexpression to cancer cell survival and immune evasion under metabolic stress. Elevated GYS1 activity has been implicated in tumor adaptation to nutrient-poor environments-particularly in aggressive cancers such as ovarian, breast, and pancreatic malignancies-making it an attractive and underexplored therapeutic target.
"Our new SKOV3-GYS1+ cell line represents a versatile, ready-to-use system for biotech and pharma partners looking to evaluate GYS1-targeted compounds," said Dr. David Aguilar, SOHM's COO. "This is just one example of how ABBIE™ enables the rapid and precise engineering of human cell models to match emerging research priorities."
The ABBIE™ gene editing platform is designed for high specificity and fast turnaround, enabling SOHM to customize cell lines across a range of oncology and rare disease applications. ABBIE™ delivers high efficiency with low off-target effects, streamlining the development of disease-relevant screening models without the need for viral vectors.
SOHM plans to expand its engineered cell line portfolio to include other metabolic and immuno-oncology targets in 2025, aiming to empower early-stage drug developers with physiologically relevant models for high-throughput compound screening.
About SOHM, Inc.
SOHM is a US-based pharmaceutical and biotechnology company focused on developing and manufacturing cutting-edge therapeutic solutions, including cell and gene therapies, to address unmet medical needs globally. With the ABBIE™ gene editing platform, SOHM is unlocking a new era of customized disease models to support drug discovery, from bench to bedside.
Safe Harbor Statement
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
Media Contact:
SOHM, Inc.
714-522-6700
info@sohm.com
SOURCE: SOHM, Inc
View the original press release on ACCESS Newswire
FAQ
What is the significance of SOHM's new GYS1 ovarian cancer cell line?
How does SHMN's ABBIE platform work in gene editing?
What are SOHM's (SHMN) plans for cell line development in 2025?
Why is GYS1 an important target for cancer treatment?
